Study to evaluate oxygen therapy effects on physical activity in patients with fibrotic interstitial lung disease who experience low oxygen levels during exercise

3 1 1 1

What is this study about?

This study focuses on patients with fibrotic interstitial lung disease, a condition that causes scarring of the lung tissue and makes breathing difficult. The study specifically looks at patients who experience low oxygen levels (hypoxemia) during physical activity. The treatment being investigated is oxygen therapy, which involves breathing in additional oxygen through specialized equipment.

The purpose of this research is to evaluate how oxygen therapy affects daily physical activity in patients when they exert themselves. The study measures this by tracking the number of steps patients take each day using a special device called an accelerometer. Patients will be monitored for three months to see how oxygen therapy impacts their ability to be physically active.

During the study, some participants will receive oxygen therapy while performing physical activities, while others will serve as a comparison group. The research will look at various aspects of patients’ health, including their breathing difficulties, quality of life, and certain blood markers. The amount of time patients use their oxygen therapy each day will also be tracked.

1 Initial assessment

Your eligibility for the study will be confirmed through medical evaluation of your fibrotic interstitial lung disease diagnosis

A breathing test called 6-minute walk test will be performed to measure your oxygen levels during physical activity

Your respiratory symptoms will be evaluated to confirm stability over the previous two weeks

2 Study group assignment

You will be assigned to either the control group or the intervention group

If assigned to the intervention group, you will receive oxygen therapy during physical activities

You will receive instructions on how to use the oxygen delivery system for inhalation

3 Activity monitoring

You will wear an accelerometer device that counts your daily steps

The device will track your physical activity levels throughout the study period

Your daily step count will be recorded and analyzed

4 Questionnaires and assessments

You will complete questionnaires about your breathing difficulties (dyspnea-12)

Your quality of life will be evaluated using a specific assessment (K-BILD)

Levels of anxiety and depression will be measured (HADS questionnaire)

5 Follow-up evaluations

Your progress will be evaluated after one month of participation

A final assessment will be conducted after three months

Blood samples will be collected to analyze oxidative stress levels

Who Can Join the Study?

  • Must be 18 years of age or older
  • Must have been diagnosed with fibrotic interstitial lung disease, confirmed by a chest CT scan showing specific features like:
    • Scarring around the edges of the lungs
    • Enlarged airways due to scarring
    • Decreased lung volume
    • Honeycomb-like appearance in lung tissue
  • Must show low oxygen levels during exercise, specifically an oxygen saturation level of 88% or lower during a 6-minute walking test when breathing regular room air
  • Must have stable breathing symptoms for at least two weeks before joining the study
  • Both men and women can participate

Who Cannot Join the Study?

  • Patients under 18 years of age
  • Patients who cannot perform physical activity due to severe medical conditions
  • Patients with unstable heart conditions (such as recent heart attack or uncontrolled heart rhythm problems)
  • Patients with severe pulmonary hypertension (high blood pressure in the lungs’ arteries)
  • Patients who are currently participating in other clinical trials
  • Patients who are unable to use an accelerometer (step-counting device) properly
  • Patients who are currently using oxygen therapy at home
  • Patients with cognitive impairment that would prevent them from following study instructions
  • Patients who cannot complete the 6-minute walk test (a test measuring how far you can walk in 6 minutes)
  • Pregnant or breastfeeding women
  • Patients with other severe medical conditions that could interfere with study participation

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Consorci Mar Parc De Salut De Barcelona Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Recruiting
04.03.2024

Trial locations

Investigated drugs:

Oxygen therapy

Oxygen therapy is a medical treatment that provides additional oxygen to patients who have difficulty getting enough oxygen naturally. In this study, it is used to help patients with lung disease breathe better during physical activities. The oxygen is typically delivered through a nasal cannula (small tubes that fit in the nose) or a mask, allowing patients to move around while receiving the supplemental oxygen they need. This therapy is particularly important for patients who experience low oxygen levels when they exercise or perform physical activities.

Investigated diseases:

Fibrotic Interstitial Lung Disease – A group of chronic lung disorders characterized by inflammation and scarring (fibrosis) of the lung tissue between the air sacs. The disease causes the lungs to become stiff and thick, making it increasingly difficult to breathe. The condition typically develops gradually, with progressive scarring of the delicate tissues in the lungs. As the disease advances, it affects the ability to transfer oxygen from the lungs into the bloodstream, particularly during physical activity. The scarring process can affect different parts of the lungs, including the walls of the air sacs, the airways, and the surrounding tissue.

Trial ID:
2023-510440-20-00
Protocol code:
AFOX
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +1
  • A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

    Recruiting

    3 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +4